Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
75%(6 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_3
1
11%
Ph phase_2
2
22%
Ph phase_4
4
44%

Phase Distribution

2

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
4(44.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 22 (22.2%)
Phase 31 (11.1%)
Phase 44 (44.4%)

Trials by Status

terminated111%
completed889%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

NCT02215122
completedphase_3

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
terminatedphase_4

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
completedphase_2

Environmental Control as Add-on Therapy in Childhood Asthma

NCT02251379
completedphase_1

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers

NCT03751202
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02215122Phase 1

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

Completed
NCT02175771Phase 3

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Completed
NCT03219866Phase 4

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

Terminated
NCT02251379Phase 2

Environmental Control as Add-on Therapy in Childhood Asthma

Completed
NCT03751202Phase 1

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers

Completed
NCT01772368Phase 2

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Completed
NCT00974246Phase 4

The Effect on Depressive Symptoms in ECF Residents With COPD

Completed
NCT00296491Phase 4

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Completed
NCT00400608Phase 4

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9